Aug 15 (Reuters) - The U.S. Food and Drug Administration
approved AstraZeneca's ( AZN ) blockbuster cancer drug, Imfinzi, for the
treatment of patients with a type of non-small cell lung cancer
on Thursday.
(Reporting by Christy Santhosh; Editing by Anil D'Silva)